Author:
Tan Qin-You,Li Huan-De,Zhu Rong-Hua,Zhang Qi-Zhi,Zhang Jun,Peng Wen-Xing
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine,General Medicine
Reference20 articles.
1. Cocco G, Rousseau MF, Bouvy T, et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol. 1992;20(1):131–8.
2. Beinart SC, Sales AE, Spertus JA, et al. Impact of angina burden and other factors on treatment satisfaction after acute coronary syndromes. Am Heart J. 2003;146(4):646–52.
3. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375–82.
4. Rousseau MF, Pouleur H, Cocco G, et al. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 2005;95(3):311–6.
5. Chaitman BR. Ranolazine for the treatment of chronic angia and potential use in other cardiovascular conditions. Circulation. 2006;113:2462–72.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献